	US 12,274,713 B2
	Nutraceutical composition comprising a water-soluble fullerene and a ketone
Max C. Champie, Buena Vista, CO (US)
Assigned to Max C. Champie, Buena Vista, CO (US)
Filed by Max C. Champie, Buena Vista, CO (US)
Filed on May 6, 2022, as Appl. No. 17/738,801.
Claims priority of provisional application 63/273,009, filed on Oct. 28, 2021.
Claims priority of provisional application 63/185,540, filed on May 7, 2021.
Prior Publication US 2022/0354886 A1, Nov. 10, 2022
Int. Cl. A61K 33/44 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01); A61P 25/28 (2006.01)

CPC A61K 33/44 (2013.01) [A61K 47/542 (2017.08); A61K 47/6923 (2017.08); A61P 25/28 (2018.01)]

7 Claims

1. A method of increasing activity in damaged or quiescent central nervous system neurons, comprising orally administering, to an individual in need of treatment for a central nervous system condition, a composition comprising:

orally administering a formulation comprising a water-soluble fullerene and a ketone at a baseline dosage of from 0.01 mg/kg to 1 g/kg, wherein the molar ratio of the water soluble fullerene to the ketone is from 1:1 to 1:50,000;

wherein the water-soluble fullerene and the ketone are provided in a ratio effective to increase activity in a quiescent neuron of the individual's central nervous system within 20 minutes.